Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2024-11-19 00:00:00 ET · period of report 2024-11-14 · accession 0001415889-24-027297 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-19 | 2024-11-14 | TBPH | Winningham Rick E | CEO, Dir | A - Grant | $9.57 | +3,193 | 1.83M | +0.2% | +$30.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-11-14 | A | A | 3,193 | $9.57 | 1,827,092 | D | — | — |